Le Lézard
Classified in: Business

Fannie Mae Prices a $802 Million Multifamily DUS REMIC (FNA 2019-M12) Under Its GeMS Program


WASHINGTON, July 18, 2019 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) priced its seventh Multifamily DUS® REMIC in 2019 totaling $802 million under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMStm) program on July 16, 2019.

"The M12 marks Fannie Mae's 90th GeMS deal since Fannie Mae's trading desk began to market its own REMIC products under the banner in 2011," said Dan Dresser, Vice President Capital Markets & Pricing. "As much as the GeMS program enables Fannie Mae to customize structures for investors, its sister program, ACES, provides that same opportunity for all DUS market participants ? investor and broker-dealer alike. As this low interest rate environment settles in and the market attempts to cope with high premium bonds, Fannie Mae's Multifamily program offers the flexibility to structure a portfolio solution."

All classes of FNA 2019-M12 are guaranteed by Fannie Mae with respect to the full and timely payment of interest and principal. The structure details for the multi-tranche offering can be found in the table below:

Class

Original Face

Weighted Average Life

Coupon (%)

Coupon Type

Spread

Offered

Price

A1

$41,300,000

6.87

2.414

FIX

S+47

100

A2

$521,111,232

9.71

2.885

FIX

S+60

102

A3

$240,000,000

9.85

2.843

FIX

S+56

101.96

X

$562,411,232

9.04

0.703

WAC IO

Not offered

Not offered

X3

$240,000,000

9.35

0.711

WAC IO

Not offered

Not offered

Total

$802,411,232






 

Group 1 Collateral




UPB:

$802,411,232

Collateral:

58 Fannie Mae DUS MBS

Geographic Distribution:

CA (22.02%), PA (20.16%), VA (11.76%)

Weighted Average


Debt Service Coverage Ratio (DSCR):

1.53x

Weighted Average


Loan-to-Value (LTV):

67.5%

For additional information, please refer to the Fannie Mae GeMS REMIC Term Sheet (FNA 2019-M12) available on the Fannie Mae GeMS Archive page http://www.fanniemae.com/portal/jsp/mbs/mbsmultifamily/gems_archive.html.

Certain statements in this release may be considered forward-looking statements within the meaning of federal securities laws. In addition, not all securities will have the characteristics discussed in this release. Before investing in any Fannie Mae issued security, you should read the prospectus and prospectus supplement pursuant to which such security is offered. You should also read our most current Annual Report on Form 10-K and our reports on Form 10-Q and Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") available on the Investor Relations page of our Web site at www.fanniemae.com and on the SEC's Web site at www.sec.gov.

Fannie Mae helps make the 30-year fixed-rate mortgage and affordable rental housing possible for millions of Americans. We partner with lenders to create housing opportunities for families across the country. We are driving positive changes in housing finance to make the home buying process easier, while reducing costs and risk. To learn more, visit fanniemae.com and follow us on twitter.com/fanniemae.

 

SOURCE Fannie Mae


These press releases may also interest you

at 08:55
Pond Technologies Holdings Inc. ("Pond"), is pleased to announce that on October 18, 2019 its subsidiary PaiGE Growth Technologies Inc. ("PaiGE") entered into a Memorandum of Understanding ("MOU") with CubicFarm Systems Corp. ("CubicFarms") to study...

at 08:50
Golden Leaf Holdings, ("Golden Leaf" or the "Company"), a pioneering cannabis company with cultivation, production and retail built around recognized brands, announced the appointment of Jane Sullivan to the newly created role of Chief People...

at 08:49
Parker Drilling Company ("Parker" or the "Company") announced today that it has filed a revised preliminary proxy statement with the Securities and Exchange Commission (the "SEC") relating to a proposal by its Board of Directors (the "Board") to...

at 08:45
CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction,...

at 08:45
Acute myeloid leukemia (AML) is an orphan's disease. The FDA defines an orphan's disease as a condition that affects fewer than 200,000 people nationwide. Before the passage of rare disease laws in the United States, patients diagnosed with a rare...

at 08:45
Legrand North & Central America, the global specialist in electrical and digital building infrastructures, today announced a partnership that brings Wattstopper Human Centric Lighting (HCL) capabilities to Pinnacle Architectural Lighting's luminaires...



News published on 18 july 2019 at 11:17 and distributed by: